It is common knowledge that once diagnosed with allergy, a person has to avoid many things to prevent complications. Prevention is still the key to treatment, but this also requires accurate identification of the allergens or substances causing the allergy.
Considered a breakthrough in allergy diagnosis, the Phadia ImmunoCAP blood test provides accurate diagnosis of allergy. This advanced technology, used in identifying allergy, also aids in ruling in or ruling out allergy and identifying allergic triggers.
The test provides a clinically relevant means of confirming or excluding the presence of allergy in patients with upper respiratory diseases. It identifies, with accuracy, specific allergen sensitivities in patients with confirmed allergy.
ImmunoCAP is now considered by many allergy experts as state-of-the-art, particularly in the detection of specific IgE (Immunoglobulin E), an established allergy marker in human serum.
It is intended for in vitro diagnosis and aids in the clinical diagnosis of IgE mediated allergic disorders in conjunction with other clinical findings.
ImmunoCAP has provided enormous improvement in the blood allergy test technology. It has cellulose polymer in a plastic reserve. This unique technology provides high binding capacity of clinically relevant allergen proteins, including those present in very low levels.
It is World Health Organization-calibrated and thus offers accurate results and increased sensitivity, specificity, and reproducibility, equaling the most advanced in vitro allergy testing found today. It makes it possible to check the allergy development in a patient over a period of time
ImmunoCAP is the first allergy testing device which received an approval from the US Food and Drug Administration (USFDA) for providing quantitative measurement of IgE.
A recent study published in the Journal of Allergy and Clinical Immunology presented that ImmunoCAP is the standard for accurate and reliable quantitative IgE test.
This device was developed by Phadia AB, in Uppsala, Sweden, the world leader in in-vitro IgE diagnostic research and product development.
Anyone with nasal or other allergy-like symptoms is eligible for specific IgE testing. It can be done on patients of any age regardless of skin condition.
There is no need to stop medication prior to the drawing of a blood sample. Only one blood sample is needed and it can be saved and used several times if complementary tests are requested or required.
This advanced technology for allergy diagnosis is now available in modern Philippine hospitals and laboratories. In Metro Manila, it is found in the following hospitals: Medical City, Makati Medical Center, Manila Doctors Hospital, National Kidney Institute, Philippine General Hospital, Fe del Mundo Medical Center, Victor R. Potenciano Medical Center and Clinica Manila.
For people living outside Metro Manila, they can visit these sites for the allergy test at Our Lady of Mt. Carmel Medical Center (Pampanga), St. Patrick’s Hospital Medical Center (Batangas), Laguna Health Services Coop Lab (Laguna), Wellcare Clinics and Lab. Inc., (Cavite and Laguna), and Our Lady of Mercy Diagnostic Center (Davao City).
For inquiries on allergy testing and ImmunoCAP, call the Trianon hotline at 815-3239 or visit www.phadia.com.